| August 21, 2014 | ISSUE NUMBER 365 VOL 4 |
Global Health
Ebola Outbreak Raises Ethical Issues
The development of new treatments and preventives to combat the lethal Ebola virus has been slow, marked by caution at public health agencies to approve testing of high-risk compounds and biopharma’s reluctance to invest in a field with limited market potential. But all that has now changed. Jill Wechsler reports on the global efforts to facilitate access to experimental drugs and vaccines ...Read more
Is your key account management program delivering the results you need?  Read this article to learn the three fundamental questions you should ask to assess your key account management program.
Trade & Investment
The Transatlantic Trade and Investment Partnership: From Hot TTIP to Oblivion?
Only a year ago, hopes were high of rapid progress towards a transatlantic trade deal that would boost the European and US economies. The Transatlantic Trade and Investment Partnership was the hot tip for a 2014 success story. But the latest read-out of progress suggests that rather than remaining a hot tip, TTIP now risks being tipped into oblivion. Reflector reports
...Read more
The lifecycle of a new product is shorter, more contested, full of regulatory delays, and beset by a challenging access and reimbursement environment. Learn how to wrest maximum value from every stage of the lifecycle – from access to acquisition to adherence –  by downloading this eBook.
Recruitment and Retention
Mind the (Generation) Gap: The Hunt for Talent in Asia-Pac
As more global life sciences firms see their Asian businesses skyrocket, the search for strong, internationally savvy talent in Asia-Pacific has never been more competitive. Susan Macdonald talks to Thomas Meininghaus of Siemens Audiology Solutions about the unique challenges of recruiting to fill senior roles in Asia
...Read more
Deals
The History (and Future) of Pharma M&As
As the pharmaceutical market expands internationally, companies have realised that carefully thought-out M&As can open up new geographical advantages. Although the pharma markets of US, Europe and Japan still represent the majority of global sales, emerging markets are growing at a faster annual rate, writes Faiz Kermani
...Read more
|
|
|
|
 //Allergan (Irvine, CA), the makers of Botox, announced that its Chief Financial Officer (CFO), Jeff Edwards, is stepping down. Jim Hindman, a 30-year company veteran, will assume the position of CFO. The move is part of Allergan’s battle to prevent a hostile takeover by Canadian firm Valeant Pharmaceuticals.//Cytori Therapeutics (San Diego, CA) announced that Mr. Tiago Girão has been appointed Vice President of Finance and Chief Financial Officer, effective September 2.//North Carolina Biotechnology Center (Research Triangle Park, NC) named Douglas L. Edgeton as its new President and CEO.//Cyanotech Corporation (Kailua-Kona, HI) appointed Gerard “Gerry” Watts to the newly created position as Chief Operations Officer.//
|
|
|
|
|
|
 |
|
| |
 |
|
 |
 What is your key area of concern regarding your company’s future?
|
|
|
|
